Fit the patient morphology with the appropriated probe
The new spleen stiffness measurement (SSM by VCTE™) and the embedded ultrasound localization system enable risk stratification of patients with advanced chronic liver disease and portal hypertension.
SSM by VCTE™ is unique, patented and validated for portal hypertension assessment4. It is a new marker for non-invasive evaluation of spleen stiffness. 100 peer-reviewed publications support the use of SSM by VCTE™.
LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment. It is the standard for non-invasive evaluation of liver stiffness1 with 2,250 international peer-reviewed publications.
CAP™ is unique patented and validated for liver steatosis assessment2,3 with 330 international peer-reviewed publications.
*CAP™ is available as on option.
Measurements of spleen stiffness using the FibroScan® Expert 630 equipped with the new SSM module may allow identifying esophageal varices with a high risk of bleeding. Additionally, the concomitant measurements of both hepatic and splenic stiffness can distinguish between varices caused by cirrhosis from those due to portal hypertension in the absence of cirrhosis.
Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.
References are available in our bibliography.